Preventing transfusion related complications in a recipient of a blood transfusion

• US 7,648,699 B2
• Filed: 08/31/2006
• Issued: 01/19/2010
• Est. Priority Date: 06/02/2000
• Status: Expired due to Fees

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation)
• Original Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.)
• Inventors: Li, Junzhi, Goodrich, Raymond P.
• Primary Examiner(s): Prouty; Rebecca E
• Assistant Examiner(s): Lee; Jae W
• Application Number:
  US11/469,186
• Publication Number:
  US 20070098697A1
• Time in Patent Office: 1,237 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A01N 1/0215 Disinfecting agents, e.g. antimicrobials for preserving living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61K 41/0023 Agression treatment or altering

Abstract

This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.

Claims

1. A process for reducing transfusion related complications in a human recipient due to human donor cells that may be present in an allogeneic blood transfusion comprising the steps of:

adding to the blood to be transfused a photosensitizer consisting essentially of riboflavin at a concentration of 50 μ

M;

irradiating the blood and riboflavin with light at a wavelength between 290-370 nm for around 8 minutes to reduce transfusion related complications in the recipient caused by the donor cells;

wherein the transfusion related complications are alloimmunization, Transfusion Associated Graft vs. Host Disease (TA-GvHD) or microchimerism;

transfusing the irradiated blood into a recipient; and

reducing transfusion related complications in the recipient.

2. The process of claim 1 wherein the blood to be transfused is whole blood.

3. The process of claim 1 wherein the blood to be transfused is platelets.

4. The process of claim 1 wherein the donor cells causing transfusion related complications comprise white blood cells.

5. The process of claim 1 wherein the donor cells causing transfusion related complications comprise platelets.

6. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing alloimmunization by reducing activation of the donor cells in the recipient.

7. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing alloimmunization by reducing proliferation of the donor cells in the recipient.

8. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing alloimmunization by reducing production of cytokines by the donor cells in the recipient.

9. The process of claim 1 wherein the step of reducing transfusion related complications further comprises reducing microchimerism by reducing production of antibodies by the donor cells in the recipient.